ArticleAnnals of the rheumatic diseases2021
Response to: 'COVID-19 in patients with rheumatological diseases treated with Anti-TNF' by Brito
Kristin M D'Silva, Naomi Serling-Boyd, Rachel Wallwork, Tiffany Hsu, Jeffrey A Sparks, Zachary Scott Wallace
Open access · greenAbstract readLetterComment
In one paragraphArticle in Annals of the rheumatic diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.4field-weighted citation impact, top 36% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed, 4 citations in OpenAlex.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
5 · Who and what moneyAuthors and funding
6 authors at 3 institutions in 1 country.
Kristin M D'SilvaDivision of Rheumatology, Allergy, and Immunology, Harvard Medical School, Boston, Massachusetts, USA.
Naomi Serling-BoydDivision of Rheumatology, Allergy, and Immunology, Harvard Medical School, Boston, Massachusetts, USA.
Rachel WallworkDivision of Rheumatology, Allergy, and Immunology, Harvard Medical School, Boston, Massachusetts, USA.
Tiffany HsuDivision of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Jeffrey A SparksDivision of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, Massachusetts, USA.ORCID 0000-0002-5556-4618 Zachary Scott WallaceDivision of Rheumatology, Allergy, and Immunology, Harvard Medical School, Boston, Massachusetts, USA zswallace@partners.org.ORCID 0000-0003-4708-7038 Harvard University · USBrigham and Women's Hospital · USMassachusetts General Hospital · US
Funding
Research Training in Rheumatology at Massachusetts General HospitalT32AR007258 · NIAMS · MASSACHUSETTS GENERAL HOSPITAL · PI ANDREW D LUSTER · 1986 to 2026
$6.9MImpact of ANCA Type and Rituximab vs. Cyclophosphamide on Cardiovascular Risk, Mortality, and Quality-Adjusted Life Years inANCA-Associated VasculitisK23AR073334 · NIAMS · MASSACHUSETTS GENERAL HOSPITAL · PI WALLACE, ZACHARY SCOTT · 2018 to 2022
$948kNIAMS NIH HHS K23 AR073334NIAMS NIH HHS L30 AR070520NIAMS NIH HHS T32 AR007258
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
Indexed as
COVID-19Rheumatic DiseasesChinaHumansSARS-CoV-2Tumor Necrosis Factor InhibitorsTumor Necrosis Factor Inhibitorsautoimmunitybiological therapyepidemiology
Identifiers
PMID32546600
PMCPMC11881637
OpenAlexW3035132836
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390